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Abstract
Background: Prostate cancer is a leading cause of death in the male population, therefore, a
comprehensive study about the genes and the molecular networks involved in the tumoral prostate
process becomes necessary. In order to understand the biological process behind potential
biomarkers, we have analyzed a set of 57 cDNA microarrays containing ~25,000 genes.
Results:  Principal Component Analysis (PCA) combined with the Maximum-entropy Linear
Discriminant Analysis (MLDA) were applied in order to identify genes with the most discriminative
information between normal and tumoral prostatic tissues. Data analysis was carried out using
three different approaches, namely: (i) differences in gene expression levels between normal and
tumoral conditions from an univariate point of view; (ii) in a multivariate fashion using MLDA; and
(iii) with a dependence network approach. Our results show that malignant transformation in the
prostatic tissue is more related to functional connectivity changes in their dependence networks
than to differential gene expression. The MYLK, KLK2, KLK3, HAN11, LTF, CSRP1 and TGM4
genes presented significant changes in their functional connectivity between normal and tumoral
conditions and were also classified as the top seven most informative genes for the prostate cancer
genesis process by our discriminant analysis. Moreover, among the identified genes we found
classically known biomarkers and genes which are closely related to tumoral prostate, such as
KLK3 and KLK2 and several other potential ones.
Conclusion: We have demonstrated that changes in functional connectivity may be implicit in the
biological process which renders some genes more informative to discriminate between normal
and tumoral conditions. Using the proposed method, namely, MLDA, in order to analyze the
multivariate characteristic of genes, it was possible to capture the changes in dependence networks
which are related to cell transformation.
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Background
Cancer is one of the main public health problems in the
United States and worldwide [1]. Among the diverse types
of neoplasia, prostate cancer is the third most common
cancer in the World [2], being ranked as the second lead-
ing cause of death in men, the first being lung cancer [1].
Its incidence and mortality varies in different parts of the
World, being highest in Western countries, mainly among
Africans [3].
With the widespread use of the prostate-specific antigen
(PSA) test, more men are examined, and consequently,
identification of patients with asymptomatic low-stage
tumors has increased considerably [4,5]. Although the
majority of prostate cancers is confined to the prostate
gland, rarely affecting life expectancy, in about 30% of the
cases, a specialized group of cells from the primary tumor
mass may invade and colonize other distant tissues caus-
ing death, therefore, metastatic disease rather than the pri-
mary tumor itself is responsible for death, causing the
prognosis to be directly related to the spread of the tumor.
Unfortunately, the therapeutic approaches used nowa-
days against advanced stages of prostatic cancers are not
effective [6]. Therefore, it is extremely important to under-
stand the basic molecular biology involved in this disease
in order to prevent the progression of the tumor [6]. How-
ever, the identification and analysis of these molecular
mechanisms has been hampered by the heterogeneity and
high molecular complexity of the process involved in the
development of this disease.
In the last few years, several efforts have been made
towards determining the genetic mechanisms involved in
the development of this tumor [6,7]. A widely used
approach in studying the development of several types of
cancers has been the high-throughput gene expression
microarray analysis, which has provided a wealth of infor-
mation about tumor marker genes. Conventional meth-
ods of microarray data analysis have been systematically
used to examine the differentially expressed genes [8], and
molecular pathways [9] and discriminative methods have
been used in order to identify biomarkers [10,11].
In general, discriminant studies focus only on the classifi-
cation accuracy of the method and on a pre-step selection
of the features (genes) which best classifies the samples
[12]. This selection of features is often carried out by
selecting a subgroup of the most differentially expressed
genes [13] or in a multivariate fashion [12]. However,
understanding of the structure responsible for regulation
of these discriminative set of genes in prostatic cancer is
required [14].
Many years of intensive research have demonstrated that
signaling molecules are organized into complex biochem-
ical networks. These signaling circuits are complicated sys-
tems consisting of multiple elements interacting in a
multifarious fashion. Signaling networks are regulated
both in time and space [15]; allow the cell to decide which
cellular process (cell division, differentiation, transforma-
tion, or apoptosis) is the most appropriate response for
each situation. Due to the high connectivity and complex-
ity of these biological systems, small modifications in a
few members ("hub" genes, i.e., highly functionally con-
nected genes) of these biochemical networks are sufficient
to perturb the whole system [16], consequently resulting
in a change on the cell's phenotype [17]. Frequently,
changes in the relative concentration of molecules, such
as mRNAs and proteins, are the unique parameter ana-
lyzed in biological systems. However, the biomolecules'
concentration is not the only important variable, but their
compartmentalization and diffusion are also determi-
nants of the cell's phenotype. Therefore, these approaches
are reductionists in defining a good biomarker as the most
differentially expressed gene or protein when comparing
distinct cellular contexts.
Here, we report a cDNA microarray-based study in pros-
tatic cancer aimed at understanding why some genes are
good predictors in discriminating normal versus tumoral
samples and others are not. We demonstrate that the dis-
criminative information between normal and tumoral
prostates is related to the change in functional connectiv-
ity between certain genes and not necessarily in their dif-
ferential expression, as has often been assumed.
Moreover, we present a systematic and straightforward
approach based on MLDA (Maximum-entropy Linear Dis-
criminant Analysis) to identify putative biomarkers in
high dimensional data (when the number of features is
greater than the number of observations), and a depend-
ence network analysis in order to interprete sets of dis-
criminative genes. This idea is illustrated in Figure 1.
Results
Simulation
The combination of PCA (Principal Component Analysis)
+ MLDA (Maximum-entropy Linear Discriminant Analy-
sis) [18] was applied in a simulated data described in the
Methods section in order to demonstrate that functional
connectivity changes may be captured by the proposed
approach. Figure 2 describes the weights in absolute val-
ues attributed by MLDA to each feature (artifically gener-
ated genes). The features are sorted in a decreasing order
of weight. Red crosses represent the genes which have
their functional connectivity alterated between conditions
1 and 2. Blue crosses represent the genes which have their
connectivities unaltered.
Samples classification
Applying the PCA combined with the MLDA approach to
all ~25,000 genes available in our microarray dataset [19],
it was possible to classify the samples with an accuracy ofBMC Systems Biology 2008, 2:106 http://www.biomedcentral.com/1752-0509/2/106
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96.5% (a misclassification of 2 out of 57 samples), using
a leave-one-out cross validation.
Projection matrix ψMLDA analysis
The projection matrix ψMLDA contains the weights (degree
of relationship between the gene and the normal/tumoral
state) for each feature (gene). Figure 3 describes the
weights in absolute values attributed by MLDA to each
gene. The genes are sorted in a decreasing order of weight.
The most informative genes correlated to prostatic cancer
Table 1 illustrates the top 100 features identified as the
most informative genes related to malignant transforma-
tion by the PCA+MLDA approach ranked in a decreasing
order of weight values. This set of 100 most informative
genes represents ~0.4% of the total number of genes avail-
able in the microarrays (~25,000 genes). Notice that these
100 genes have a MLDA weight different from zero, i.e.,
the 100th gene RPS28 has a MLDA weight (~0.035, Table
1) located before the convergence of the curve to zero
(Figure 3, the horizontal red line indicates the 100th
gene). In order to verify the stability and robustness of our
results, 27 observations out of 32 from normal sample
and 20 out of 25 from tumoral sample were randomly
selected and the ψMLDA was re-calculated. This step was
A pictorial scheme of the combination of PCA+MLDA and  dependence network analysis for two populations (normal  and tumoral prostatic tissues) Figure 1
A pictorial scheme of the combination of 
PCA+MLDA and dependence network analysis for 
two populations (normal and tumoral prostatic tis-
sues).
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The discriminative weight of each simulated feature Figure 2
The discriminative weight of each simulated feature. 
The features are sorted (in decreasing order) by the absolute 
value of the weight. Red crosses represent the 500 features 
that have their functional connectivities alterated between 
conditions 1 and 2. Blue crosses represent the 24,500 fea-
tures which have their functional connectivities unaltered.
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performed 100 times and the mean rank for each gene was
obtained. About 80% of the originally obtained top 100
most discriminative genes were ranked as the top 100
most discriminative genes.
We have also manually annotated (which we believe be
more accurate than automatic computer-based annota-
tion, since it may be more efficient to capture semantic
information from published articles) this set of 100 genes
[see Table 1 and Additional file 1].
Putative differentially expressed genes
We have also searched for differentially expressed genes.
About 25% of the genes listed in Table 1 do not present
statistical evidence to be differentially expressed between
normal and tumoral conditions.
Relevance networks
Both normal and tumoral relevance networks with the top
100 most informative genes were constructed, consider-
ing a false discovery rate of 5%, being illustrated in Figures
4 and 5, respectively. Nodes in red are the genes which
have their functional connectivity (estimated using the
non-parametric Hoeffding's D measure [20]) changed
considerably between normal versus tumoral conditions,
i.e., they become "hubs" (highly connected genes) [16] in
tumoral prostates. "Hub" genes were maintained also
when relevance networks were constructed under differ-
ent FDR thresholds (1, 5 and 10%).
Discussion
Firstly, the PCA+MLDA approach was applied to a simu-
lated data set in order to illustrate that differences in con-
nectivity may be behind the oncogenesis process. Sato et
al. (2008) [21] have already demonstrated in another con-
text (neuroscience) that the information contained in the
connectivity may be useful to sample classification. The
simulation was performed in a large scale multidimen-
sional condition, where the relevant features (genes which
have the connectivity changed) are only 2% (500 out of
25,000 genes). Interestinlgy, MLDA was able to correctly
identify the discriminative features, represented by red
crosses in Figure 2. Notice that the relevant features for
discrimination do not present differential expression
between conditions 1 and 2 (by construction).
In order to verify whether gene expression data contain
the information to discriminate normal from tumoral
prostatic samples, we have applied the PCA+MLDA
approach to actual biological data, obtaining a high clas-
sification accuracy (96.5%) by the leave-one-out cross-
validation. In this case, we have used all the principal
components in order to avoid losing information. PCA is
applied regarding computational cost and memory limi-
tation. It is important to mention that the numerical
results are identical in the absence of the PCA step [22].
Notice that MLDA does not require a pre-step feature
selection, because it may also work for high dimensional
data. Therefore, it was possible to include all of the 25,000
genes of the microarray dataset.
Since it was possible to verify that gene expression data
retains information for classification, we analyzed the
ψMLDA projection matrix which contains the weight values
for each feature (gene). Notice that the majority of the
genes shown in Figure 3 have weights near zero, and only
a few genes actually have discriminative information
(high weight).
By analyzing Table 1, it is possible to verify that most of
the 100 informative genes had already been described in
the literature as genes related to cancer (76 genes) and 45
genes had specifically been associated to prostate tumor.
Interestingly, most of the other 24 genes do not have ref-
erences describing their functionality. Therefore, they may
be associated to cancer but have not been studied yet. The
description of the 76 genes in the literature corroborates
the results obtained by the PCA+MLDA method, indicat-
ing that these genes are informative to discriminate
between normal and tumoral samples. The stability and
robustnees of this result were verified by obtaining
around 80% of the same top 100 genes when five obser-
The discriminative weight of each gene Figure 3
The discriminative weight of each gene. The genes are 
sorted (in decreasing order) by the absolute value of the 
weight. The horizontal red line indicates the 100th gene.BMC Systems Biology 2008, 2:106 http://www.biomedcentral.com/1752-0509/2/106
Page 5 of 14
(page number not for citation purposes)
Table 1: ψMLDA: the weights attributed by MLDA.
Gene name Official Full Name ψMLDA p-value (Wilcoxon) References:
1 *MYLK myosin light chain kinase 0.14672 0.00000 [24]
2 *KLK2 kallikrein-related peptidase 2 0.12512 0.01053 [49]
3* KLK3 kallikrein-related peptidase 3 0.12032 0.05625 [50]
4 HAN11 WD repeat domain 68 0.12019 0.00000
5 *LTF lactotransferrin 0.11594 0.00092 [39]
6 CSRP1 cysteine and glycine-rich protein 1 0.11355 0.00000 [51]
7* TGM4 transglutaminase 4 (prostate) 0.10452 0.06063 [42]
8 *ACTG2 actin gamma 2 smooth muscle enteric 0.09826 0.00000 [52]
9 MYL6 myosin light chain 6 alkali smooth muscle and non-muscle 0.09817 0.00045 [53]
10 *RDH11 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 0.09583 0.00018 [54]
11 *AZGP1 alpha-2-glycoprotein 1 zinc-binding 0.08817 0.00059 [55]
12 NPAL3 NIPA-like domain containing 3 0.08478 0.00008
13 PRO1073 PRO1073 protein 0.08077 0.28733
14 *FXYD3 FXYD domain containing ion transport regulator 3 0.08024 0.05417 [56]
15 TPM2 tropomyosin 2 (beta) 0.07919 0.00001 [57]
16 CRYAB crystallin alpha B 0.07560 0.00000 [58]
17 ACTA2 actin alpha 2 smooth muscle aorta 0.07372 0.01610 [59]
18 *RPS6 ribosomal protein S6 0.07323 0.12130 [60]
19 TMEM130 transmembrane protein 130 0.07296 0.00005
20 *ACPP acid phosphatase prostate 0.07185 0.00037 [61]
21 *PCP4 Purkinje cell protein 4 0.07128 0.00000 [62]
22 *SYNPO2 synaptopodin 2 0.06943 0.00000 [63]
23 *SORBS1 sorbin and SH3 domain containing 1 0.06773 0.00000 [64]
24 *MSMB microseminoprotein beta 0.06588 0.00076 [65]
25 ACTC actin alpha cardiac muscle 1 0.06335 0.00001
26 *TGFB3 transforming growth factor beta 3 0.06313 0.00000 [66]
27 *MALT1 mucosa associated lymphoid tissue lymphoma translocation gene 1 0.06205 0.14208 [67]
28 ZNF532 zinc finger protein 532 0.06131 0.00000
29 ANXA1 annexin A1 0.06119 0.00001 [68]
30 PALLD palladin cytoskeletal associated protein 0.06116 0.00000 [69]
31 *MT2A metallothionein 2A 0.06054 0.00141 [70]
32 ING5 inhibitor of growth family member 5 0.05872 0.93009 [71]
33 PGM5 phosphoglucomutase 5 0.05862 0.00000
34 SERPINA3 serpin peptidase inhibitor clade A (alpha-1 antiproteinase antitrypsin) 
member 3
0.05828 0.19710 [72]
35 *KRT5 keratin 5 
(epidermolysis bullosa simplex Dowling-Meara/Kobner/Weber-Cockayne 
types)
0.05699 0.00000 [73]
36 RPL5 ribosomal protein L5 0.05589 0.53873 [74]
37 *IGF1 insulin-like growth factor 1 (somatomedin C) 0.05549 0.00000 [75]
38 ZNF92 zinc finger protein 92 (HTF12) 0.05388 0.16056
39 *FOLH1 folate hydrolase (prostate-specific membrane antigen) 1 0.05361 0.08683 [76]
40 *CYR61 cysteine-rich angiogenic inducer 61 0.05318 0.00020 [77]
41 FHL1 four and a half LIM domains 1 0.05305 0.00000 [78]
42 *H19 H19 imprinted maternally expressed transcript 0.05221 0.00006 [79]
43 DMN desmuslin 0.05219 0.00000
44 NEFH neurofilament heavy polypeptide 200 kDa 0.05186 0.00001 [80]
45 PPP1R12B protein phosphatase 1 regulatory (inhibitor) subunit 12B 0.05149 0.00000
46 ANTXR2 anthrax toxin receptor 2 0.05141 0.00002 [81]
47 MRLC2 myosin regulatory light chain MRLC2 0.05056 0.02204 [82]
48 C20orf103 chromosome 20 open reading frame 103 0.05055 0.00150
49 UBA52 ubiquitin A-52 residue ribosomal protein fusion product 1 0.05033 0.00518 [83]
50 TRGV9 T cell receptor gamma variable 9 0.04983 0.00190
51 *SPARC secreted protein acidic cysteine-rich (osteonectin) 0.04969 0.00240 [84]
52 *AMACR alpha-methylacyl-CoA racemase 0.04903 0.00011 [85]
53 DNER delta/notch-like EGF repeat containing 0.04809 0.09301 [86]
54 PRNP prion protein (p27-30) 0.04806 0.00000 [87]
55 PDK4 pyruvate dehydrogenase kinase isozyme 4 0.04751 0.00002 [88]
56 *APOD apolipoprotein D 0.04744 0.12931 [89]BMC Systems Biology 2008, 2:106 http://www.biomedcentral.com/1752-0509/2/106
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vations were excluded randomly from normal sample and
five from tumoral sample in 100 re-calculations. For more
details about annotation of the top 100 genes and the
complete list of the ~25,000 genes, please see Additional
file 2.
Comparing the weights obtained by MLDA and the differ-
entially expressed genes, it is surprising that the most dif-
ferentially expressed genes are not necessarily the most
discriminative ones. In other words, a multivariate combi-
nation of genes may be regulating the normal/tumoral
state, i.e., the combination of genes may contain more
information about normal/tumoral conditions than an
univariate differentially expressed gene.
Since it is known that a complex network is involved in
the regulation of several molecular processes, we further
analyzed the dependence network involved in these puta-
57 *HERPUD1 homocysteine-inducible endoplasmic reticulum stress-inducible ubiquitin-like 
domain member 1
0.04695 0.00001 [90]
58 FSTL1 follistatin-like 1 0.04692 0.00092 [91]
59 HSPCB heat shock protein 90 kDa alpha (cytosolic) class B member 1 0.04663 0.08386 [92]
60 *GSTM2 glutathione S-transferase M2 (muscle) 0.04446 0.00000 [93]
61 *PTN pleiotrophin 0.04440 0.00000 [94]
62 *ERG v-ets erythroblastosis virus E26 oncogene homolog (avian) 0.04410 0.06528 [95]
63 *CTGF connective tissue growth factor 0.04342 0.00004 [96]
64 *GUCY1A3 guanylate cyclase 1 soluble alpha 3 0.04303 0.05841 [97]
65 MT1F metallothionein 1F 0.04303 0.00002 [98]
66 *TIMP3 TIMP metallopeptidase inhibitor 3 0.04225 0.00000 [99]
67 *LDHB lactate dehydrogenase B 0.04217 0.00000 [100]
68 RNASE4 ribonuclease RNase A family 4 0.04167 0.00000
69 ANPEP alanyl aminopeptidase 0.04165 0.00002 [101]
70 *CAV1 caveolin 1 caveolae protein 22 kDa 0.04135 0.00000 [102]
71 TM9SF2 transmembrane 9 superfamily member 2 0.04122 0.01275
72 *HSPB8 heat shock 22 kDa protein 8 0.04088 0.00000 [103]
73 TUBA1A tubulin alpha 1a 0.04087 0.00018
74 PDLIM5 PDZ and LIM domain 5 0.04077 0.32533 [104]
75 LPP LIM domain containing preferred translocation partner in lipoma 0.04073 0.00003 [105]
76 MAD2L1B
P
MAD2L1 binding protein 0.04051 0.62639 [106]
77 *ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif 1 0.04048 0.00011 [107]
78 *RHOA ras homolog gene family member A 0.04039 0.11368 [108]
79 *TXNIP thioredoxin interacting protein 0.03995 0.00227 [109]
80 OGDH oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) 0.03974 0.07543
81 RPL35 ribosomal protein L35 0.03971 0.17555
82 *ANKH ankylosis progressive homolog (mouse) 0.03856 0.00318 [110]
83 MPST mercaptopyruvate sulfurtransferase 0.03856 0.00000 [111]
84 MORF4L2 mortality factor 4 like 2 0.03831 0.01337 [112]
85 CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 0.03799 0.00000
86 *CD9 CD9 molecule 0.03787 0.00150 [113]
87 ALDH3A2 aldehyde dehydrogenase 3 family member A2 0.03696 0.00001
88 SCN2B sodium channel voltage-gated type II beta 0.03693 0.00024 [114]
89 *SPARCL1 SPARC-like 1 (mast9 hevin) 0.03693 0.00045 [115]
90 IGJ immunoglobulin J polypeptide linker protein for immunoglobulin alpha and 
mu polypeptides
0.03683 0.00190 [116]
91 ZNF134 zinc finger protein 134 0.03670 0.00007
92 MRPL43 mitochondrial ribosomal protein L43 0.03655 0.54934
93 LOC152485 hypothetical protein LOC152485 0.03647 0.00000
94 CALM2 calmodulin 2 (phosphorylase kinase delta) 0.03622 0.05417 [117]
95 COL9A2 collagen type IX alpha 2 0.03546 0.00141
96 *PAGE4 P antigen family member 4 (prostate associated) 0.03541 0.00001 [118]
97 CALM1 calmodulin 1 (phosphorylase kinase delta) 0.03536 0.00098 [119]
98 *ACTB actin beta 0.03508 0.01159 [120]
99 *AGR2 anterior gradient homolog 2 (Xenopus laevis) 0.03498 0.56006 [121]
10
0
RPS28 ribosomal protein S28 0.03497 0.15578
*: genes already described to be related to prostatic cancer. In bold are the genes which do not present statistical evidences to be differentially 
expressed between normal and tumoral conditions.
Table 1: ψMLDA: the weights attributed by MLDA. (Continued)BMC Systems Biology 2008, 2:106 http://www.biomedcentral.com/1752-0509/2/106
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tive biomarkers in order to gain new insights. The analyis
of Figures 4 and 5 indicate that exactly the top seven most
discriminative genes described in Table 1 (MYLK, KLK2,
KLK3, HAN11, LTF, CSRP1, TGM4) have considerably
changed their functional connectivity between normal
and tumoral conditions as illustrated by red nodes in Fig-
ures 4 and 5. These seven genes become "hubs" [16], i.e.,
highly connected genes in the tumoral condition, whereas
in the normal condition, their connectivity was not differ-
ent when compared to that of other genes. Furthermore,
these seven genes maintained the position of the top
seven most discriminative ones also when we have re-
sampled the samples (the experiment which was per-
formed in order to verify the stability and robustness of
the top 100 genes). A Z-value summary table related to
these seven genes is illustrated in Table 2. Z-values
increase from normal to tumoral conditions, representing
the changes in functional connectivities between these
two conditions. The mean Z-values were calculated
between the "hub" gene and the other 99 genes. In addi-
tion, in the list of the most discriminative features, there
are genes which are more differentially expressed than
these seven ones (lower p-value), however, their connec-
tivity did not change. Krostka and Spang (2004) [17] have
already suggested that differences in co-regulation
between normal/disease states may be related to some
pathologies. Moreover, Sato et al. (2008) [21] have
reported that changes in networks connectivities may
influence classification methods. These reports support
our results showing that changes in functional connectiv-
ity may be closely related to the normal/tumoral states in
prostate and that these changes in dependence may con-
tain an additional information when compared to differ-
ential gene expression.
Almost all top seven genes identified as the most discrim-
inative features between normal and tumoral phenotypes
had previously been described in the literature as being
associated to cancer. The only gene that so far has not
been correlated to cancer is HAN11, probably because lit-
tle is known about this gene (only two articles were found
in the literature describing this gene). Five of these top
seven genes namely, MYLK, KLK2, KLK3, LTF and TGM4
had already been specifically related to prostate carci-
noma (Table 1).
Myosin light chain kinase (MYLK) is one of them. This
enzyme catalyzes the phosphorylation of a specific serine
residue on the 20 kD light chain of myosin II (MCL20),
consequently regulating the actin-myosin II interaction
[23]. This reaction is responsible for smoothing muscle
contraction/relaxation and organization of the cytoskele-
ton. Due to the central role played by the cytoskeleton in
cell division and motility, it has been demonstrated that
MYLK inhibition induces apoptosis in mammary prostate
cancer cells and inhibits the growth of mammary and
prostate tumors in rats and mice [24]. Furthermore, since
MLC20 phosphorylation is necessary for cell motility
[25,26], MYLK inhibition blocks cancer cell invasion and
adhesion in vitro. As a result, some reports described the
use of MYLK inhibitors as anti-cancer agents since they
prevent cancer cells migration [27,28].
KLK3, also known as prostate specific antigen (PSA), is
another gene which presents high functional connectivity
in tumoral samples. PSA is a serine protease, secreted into
seminal plasma, belonging to the human kallikrein gene
family, being responsible for semen liquefaction. It is the
first FDA (Food and Drug Administration)-approved
tumor marker for cancer detection [29]. The prostatic
gland volume affects the PSA level in serum, because it is
produced and secreted by prostatic tissue [30,31]. How-
ever, increased levels of KLK3 are also observed in some
patients with benign prostate hyperplasia. Therefore, ele-
vated PSA concentration in patients' plasma may be indic-
ative not only of prostate cancer, but, also of other
prostatic pathologies. Consequently, the use of PSA as a
cancer-specific marker is questioned.
Nowadays, 15 members of the kallikrein family (KLKs)
are described in humans [32]. Among the KLKs, the high-
est homology is found between PSA and KLK2. In this
case, the identity is 78% and 80% at the amino acid and
DNA level, respectively [33]. KLK2 is another gene that
presented functional connectivity changes between nor-
mal/tumoral conditions. The ratio of KLK2 to free PSA
improves the discrimination of benign prostate hyperpla-
A normal prostate relevance network constructed with the  top 100 most discriminative genes and FDR of 5% Figure 4
A normal prostate relevance network constructed 
with the top 100 most discriminative genes and FDR 
of 5%. Core genes are represented in red.BMC Systems Biology 2008, 2:106 http://www.biomedcentral.com/1752-0509/2/106
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sia and prostate cancer patients [34]. In addition, it has
already been described that KLK2 discriminates between
high and low grade tumors [35]. There is evidence indicat-
ing that KLK2 is more closely correlated to the total vol-
ume and higher grade prostate cancers than PSA [36].
Identification of both of these classic biomarkers of pros-
tate carcinomas (PSA and KLK2), in our list of the most
informative genes, provides additional evidence to the
hypothesis that functional connectivity changes and not
only differential expression levels are highly correlated to
normal/tumoral process.
Another gene classified as one of the most discriminative
prostate cancer biomarkers, whose anti-tumorigenic role
has already been described [37] is lactotransferrin (LTF).
This non-heme iron-binding glycoprotein [38] is found in
a variety of biological secretions, such as semen, as well as
in several secretions derived from glandular epithelium
cells, including the prostate. LTF mRNA and protein levels
are downregulated in prostate cancer, with significant PSA
recurrence associations, due to promoter silencing by
hypermethylation [39]. It has been reported that bovine
lactotransferrin significantly inhibits colon, esophagus,
lung, bladder and liver cancers in rats [40]. Prostate cancer
cells treated with LTF presented high apoptotic response,
growth arrest at G1 and reduced S phase, suggesting a role
for specific cell cycle regulatory mechanisms in LTF-medi-
ated cell growth inhibition [39].
CSRP1 (cysteine and glycine-rich protein 1) and TGM4
(human prostate-specific transglutaminase gene) are two
other genes that become "hubs" [16] along tumoral devel-
opment. The former belongs to the CSRP family, encod-
ing a group of LIM domain proteins, which may be
involved in regulatory processes which are important for
development and cellular differentiation. Hirasawa and
collaborators (2006) [41] suggest the use of CSRP as an
important biomarker of hepatocellular carcinoma malig-
nancy, because CSRP1 is inactivated in this model by
aberrant methylation [41]. The latter, TGM4 was
described as a candidate biomarker of region-specific epi-
thelial identity in the prostate [42], being involved in the
formation of stable protein-protein or protein-polyamide
bounds [43].
Therefore, the literature supports the suggestion that these
top seven genes (except for HAN11) may be considered as
the most closely and informative prostate cancer biomar-
kers. Consequently, this suggests that the malignant trans-
formation process in prostatic tissue is more correlated to
functional connectivity changes in the gene dependence
networks than differential gene expression itself.
Almost all of the 100 genes identified by PCA+MLDA are
correlated to cancer, and, in many cases, to prostate can-
cer. Thus, TIMP3 and ADAMTS1 (Table 1) are genes clas-
sically correlated to invasion and the metastatic process,
the main cancer attributes responsible for death.
Conclusion
In summary, our main goal using PCA+MLDA was not
dimension reduction or verification of the classification
accuracy, but to investigate the discriminative characteris-
tics extracted from the whole microarray dataset and how
one can interpret them, although this procedure may also
be used for classification, yielding good results, as previ-
ously described.
We have demonstrated that changes in functional connec-
tivity may underly the biological process which render
some genes more informative to discriminate between
normal and tumoral conditions. Using the proposed
PCA+MLDA method in order to analyze the multivariate
gene characteristic, it was possible to capture the changes
in dependence networks which are related to cell transfor-
mation. Identification of seven genes (MYLK, KLK2,
KLK3, HAN11, LTF, CSRP1, TGM4) which have their con-
nectivity altered between normal/tumoral conditions may
provide novel insights into specific targets against tumor
progression.
A tumoral prostate relevance network constructed with the  top 100 most discriminative genes and FDR of 5% Figure 5
A tumoral prostate relevance network constructed 
with the top 100 most discriminative genes and FDR 
of 5%. Core genes are represented in red.BMC Systems Biology 2008, 2:106 http://www.biomedcentral.com/1752-0509/2/106
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Methods
Principal component analysis (PCA)
Principal component analysis is a dimension reduction
technique used to reduce the high dimensional space
(number of genes).
PCA is defined as linear transformations which maps the
data to a new orthogonal coordinate system. These linear
combinations are constructed so that the greatest variance
by any projection lies on the first coordinate (called the
first principal component), the second greatest variance
on the second coordinate, and so on.
In other words, PCA summarizes the original features
information by retaining characteristics of the dataset
which most contribute to its variance.
For a gene expression data matrix X containing the genes
in the columns and the observations in the rows (normal-
ized to have zero mean and unit variance), the PCA trans-
formation matrix ψPCA is given by
ψPCA = eigenvectors(cov(XT)) (1)
where cov is the covariance matrix. In order to prevent los-
ing any variance information, ψPCA is composed of all
eigenvalues with non-zero eigenvectors. Here, PCA is used
only to reduce computational and memory costs.
Maximum-entropy linear discriminant analysis (MLDA)
In gene expression data analysis, we usually have a large
number of genes (features), but only a few number of
observations, i.e., microarrays experiments.
A critical problem in applying conventional Linear Discri-
minant Analysis (LDA) to these types of data is the singu-
larity and instability of the within-class scatter matrix
calculated when the number of features approaches the
number of available examples. In order to overcome this
limitation, we applied the MLDA approach.
The MLDA method is concerned with the stabilization of
pooled covariance matrix estimate Sp. This covariance
matrix Sp is constructed by selecting the largest disper-
sions regarding the Sp average eigenvalue. It is based on
the maximum entropy covariance selection idea devel-
oped by Thomaz et al (2004) [18].
It is known that the estimated errors of small eigenvalues
are greater than that of large eigenvalues. Therefore,
Thomaz et al. (2007) [44] proposed to expand only the
smaller and less reliable eigenvalues of Sp, keeping most
of the larger eigenvalues unchanged.
The algorithm may be described as follows:
1. Let the between-class scatter matrix Sb be defined as
and the within-class scatter matrix Sw be defined as
where  xi,  j is the m-dimensional (m: number of genes)
observation j from class ∏i (i = 1, 2, where 1 = normal and
2 = tumoral in our case) containing the gene expressions
in the rows, ni is the number of observations (microar-
rays) from class ∏i, and g is the total number of classes (g
= 2 in our case).
The vector  i is the unbiased sample mean and the matrix
Si is the sample covariance matrix of class ∏i. The mean
vector   is calculated by
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Table 2: The seven "hub" genes.
Gene name mean Z-value (normal) Standard Error mean Z-value (tumoral) Standard Error
MYLK 1.138 0.107 2.464 0.177
KLK2 0.871 0.084 1.161 0.102
KLK3 1.070 0.100 0.953 0.073
HAN11 1.305 0.142 1.502 0.141
LTF 0.862 0.080 1.750 0.127
CSRPP1 1.254 0.139 1.601 0.157
TGM4 0.869 0.116 0.956 0.121
Mean Z-values obtained by Hoeffding's D measure and the corresponding standard errors.BMC Systems Biology 2008, 2:106 http://www.biomedcentral.com/1752-0509/2/106
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where  n  is the total number of microarrays, i.e.,
.
2. Calculate the ψ eigenvectors and Λ eigenvalues of Sp,
where Sp = Sw/[n - g].
3. Calculate  , i.e., the average eigenvalue
4. Construct the new matrix of eigenvalues based on the
following largest dispersion criterion Λ* = diag [max(λi,
),..., max(λm, )]
5. Construct the modified within-class scatter matrix 
6. Finally, calculate the projection matrix ψMLDA which
maximizes the ratio of the determinant of the between-
class scatter matrix to the determinant of the within-class
scatter matrix (Fisher's criterion):
The main advantage of MLDA is that it avoids both the
singularity and instability of the within-class scatter
matrix Sw when applied directly to gene expression data,
which consists of a low number of observations and a
high number of features.
The implemented R code is available in the Additional file
3.
Simulation
This simulation was designed in order to demonstrate that
MLDA is capable to discriminate two different conditions
and also to identify the intrinsic functional connectivity
changes underlying the tumoral process. For this simula-
tion, artificial gene expressions for 25,000 genes (features)
were generated, based on the simulation illustrated in
[21]. The 25,000 genes were divided in three sets A (250
genes), B (250 genes) and C (24,500 genes). For each
gene, 30 observations representing "normal" condition
and 30 observations representing "tumoral" conditions
were generated. The model to investigate the situation
where there are fuctional connectivity changes and there is
no differences in gene expressions between conditions 1
and 2 were as follows:
ϕ(A) = 1 + 0.3ε
gene(A) = ϕA + 0.3θA
gene(B) = ϕB + 0.5θB
gene(C) = θC
where ε, , θA, θB and θC are independent Gaussian random
variables with mean of zero and variance of one. This
model considers two latent variables ϕ(A) and ϕ(B). Moreo-
ver, there is a functional relationship between A and B.
Notice that there is no difference in means between A and
B.
Differentially expressed genes
In order to identify putative differentially expressed genes,
we have applied the non-parametric Wilcoxon test under
a false discovery rate control (FDR) [45] of 5%. Wilcoxon
procedure tests the median, therefore, it is more robust to
outliers than the t-test (which tests the mean).
Relevance networks
Relevance networks [46] were constructed using the Hoef-
fding's D measure [20], a non-parametric association
method (the R code is freely available in the Hmisc pack-
age at [47]), which is more robust to outliers than the
Pearson's correlation. Pairwise correlations were meas-
ured and the false discovery rate (FDR) [45] was control-
led to 1, 5 and 10%. "Hub" genes were determined by
calculating the degree (the number of adjacent edges, i.e.
functional connectivities) of each gene and selecting the
highest ones.
Microarrays
We have analyzed the normal and tumoral prostate data-
set publicly available at the Stanford MicroArray Database
[48,19]. This dataset is composed of ~25,000 genes with
32 observations for normal state and 25 for tumoral con-
dition.
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